CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
维奈克拉联合阿扎胞苷治疗复发/难治性急性 B 淋巴细胞白血病：单中心病例系列
英文原题：Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
查看英文原题
Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
venetoclax 与 azacitidine 联合方案可能对 R/R B-ALL 患者有益。
中文摘要
目的
复发/难治性急性 B 细胞淋巴细胞白血病（R/R B-ALL）对诱导化疗往往应答不佳，但近期研究显示，一种新型药物方案可能有效。
方法
2021 年 11 月至 2022 年 8 月共纳入 8 例 R/R B-ALL 患者，均接受维奈克拉联合阿扎胞苷化疗：维奈克拉第 1 天 100 mg、第 2 天 200 mg、第 3–14 天 400 mg；阿扎胞苷第 1–7 天 75 mg/m²。
结果
8 例中有 5 例达到深度完全缓解（CR），微小残留病（MRD）低于 0.1%；1 例部分缓解，2 例未缓解。未发生严重不良事件，所有患者均耐受良好。3 例符合巩固化疗条件，并桥接至 CAR-T 治疗。
结论
维奈克拉联合阿扎胞苷方案可能使 R/R B-ALL 患者获益。
展开英文摘要原文
OBJECTIVES
Relapsed/refractory acute B-cell lymphoblastic leukemia (R/R B-ALL) often responds poorly to induction chemotherapy. However, recent research has shown a novel and effective drug treatment for R/R B-ALL.
METHODS
A total of eight patients with R/R B-ALL were enrolled in the study from November 2021 to August 2022. All patients received chemotherapy based on a combination regimen of venetoclax and azacitidine. The regimen was as follows venetoclax 100 mg d 1 , 200 mg d 2 , 400 mg d 3-14, azacitidine 75 mg/m 2 d 1-7 .
RESULTS
Five of eight patients achieved very deep and complete remission (CR) with minimal residual disease (MRD) less than 0.1%. One patient achieved partial remission. Two patients did not achieve remission. There were no serious adverse events and all patients were well tolerated. Three patients were eligible for consolidation chemotherapy and were bridged to CAR-T therapy.
CONCLUSIONS
The combined regimen of venetoclax and azacitidine may be beneficial for patients with R/R B-ALL.
论文信息
- 作者
- Hao Z、Fei Y、Chen J、Huang S、Wang L、Yu Y、Bian M、Si Y
- 单位
- Department of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, People's Republic of China.China
- 期刊
- Hematology (Amsterdam, Netherlands)2024 Dec
- 原文标识
- PubMed 38666535 · DOI 10.1080/16078454.2024.2344998